Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + CCRT +/- Ipilimumab vs Durvalumab in Stage III NSCLC
NCT04026412Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Oct 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04026412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026412.